MedTrace Logo

An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)

NCT07462130 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-03-10

No results posted yet for this study

Summary

Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease

Conditions

  • Thyroid Eye Disease

Interventions

DRUG

NTB003

NTB003 dose 1 administered SC injection every 4 weeks.

DRUG

NTB003

NTB003 dose 2 administered SC injection every 4 weeks.

DRUG

NTB003

NTB003 dose 3 administered SC injection every 4 weeks.

DRUG

NTB003 and Placebo

Drug:NTB003 subcutaneous injection Drug: Placebo subcutaneous injection

Sponsors & Collaborators

  • Nanjing Chia-tai Tianqing Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-05-31
Completion
2028-03-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462130 on ClinicalTrials.gov